Drug Approval | December 14, 2024
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Final decision from the European Commission is anticipated within the coming months
Final decision from the European Commission is anticipated within the coming months
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Subscribe To Our Newsletter & Stay Updated
